加载中
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
前收盘价
US$3.51
+US$0.12 · +3.54%
盘后
US$3.57
+US$0.06 · +1.71%
10月12日 19:59 ET
盘中时间采用ET。市场数据可能有所延迟。
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
日内区间
当前US$3.51
52周区间
当前US$3.51
盘中时间采用ET。市场数据可能有所延迟。
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
日内区间
当前US$3.51
52周区间
当前US$3.51
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 74.46万 USD | 4617.55万 USD | 5480.7万 USD | 1.13亿 USD | 9062.16万 USD |
| 销售、一般及管理费用 | 31.19万 USD | 3771.55万 USD | 4889.5万 USD | 4792.61万 USD | 3508.19万 USD |
| 营业费用 | 5910.02万 USD | 8389.1万 USD | 1.04亿 USD | 1.61亿 USD | 1.26亿 USD |
| 利息收入 | 139.6万 USD | 353万 USD | 515.17万 USD | 265.9万 USD | 119.91万 USD |
| 折旧和摊销 | — | — | 1.04亿 USD | 2000 USD | 1258 USD |
| 营业利润 | −5910.02万 USD | −8389.1万 USD | −1.04亿 USD | −1.61亿 USD | −1.26亿 USD |
| 净利润 | −5738.52万 USD | −7997.94万 USD | −9879.2万 USD | −1.57亿 USD | −1.26亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年9月30日 | 1:4 | — | — |
股票拆分 | 2015年8月12日 | 1:5 | — | — |
已生效 2019年9月30日
1:4
已生效 2015年8月12日
1:5
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1382.03万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM836.71万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF530.9万0.01%954亿 USD0.05%US$233.52-0.63%
State Street SPDR S&P Pharmaceuticals ETFXPH394.64万0.85%4.69亿 USD0.35%US$64.01-0.99%
iShares Russell 2000 Growth ETFIWO292.29万0.02%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO236.71万0.01%180亿 USD0.06%US$112.27-0.35%
AdvisorShares Psychedelics ETFPSIL211.26万4.51%4574.2万 USD1.84%US$21.26-2.32%
Vanguard Health Care ETFVHT107.92万0.00%220亿 USD0.09%US$320.67+0.52%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAdvisorShares Psychedelics ETFPSILVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
